NVST

Envista Holdings Corp. (NVST) | Rumor.io

Envista Holdings

NVST

Attention (50-day avg)0%

Attention rank (50-day avg)#3,431

Bullish sentiment (50-day avg)75%

Price to earnings ratio41.2

Market capitalization3.8B

Earnings per share0.58

Dividend yield (TTM)—

Revenue (annual)2.7B

Net income (annual)47M

Social

What share of all stock conversation is about NVST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Feb 5

Envista Holdings ($NVST) reported Q4 2025 earnings, beating estimates with adjusted EPS of $0.38 and sales of $750.6M.
The company expects FY2026 adjusted EPS of $1.35-$1.45, representing a 7-13% increase in adjusted EBITDA.
Q4 2025 core sales growth accelerated to 10.8%, with a broad-based increase in both core sales and profitability.

Generated by AI

Sentiment

Of the messages about NVST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	97.56% +1.37
Bearish	—	—	0% -100	2.44% -1.37

Feb 10

Credit Suisse raises price target for NVST to $53, citing strength in Specialty Products/Technologies and positioning for continued improvements in growth and margins throughout 2022.
Morgan Stanley maintains an Overweight rating for NVST and raises the price target to $52, driven by the company's impressive innovation-driven beat and better-than-expected 2022 guidance.
BofA raises price target for NVST to $56, citing ongoing margin expansion and 6-8% organic growth targets, with the company's revamped portfolio and new products showing significant power.

Generated by AI

Topics

Of the messages about NVST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	52.23%
Analysts	—	—	50%	30.77%
Controversies	—	—	0%	0%
Earnings	—	—	0%	12.55%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	4.45%

Announcements· Apr 19

Envista, a top-selling SUV for under $30,000, could be hardest hit by President Trump's tariffs.
General Motors' Buick brand saw a 39% sales increase in the first quarter with a refreshed lineup, including the Envista.
Tariffs may impact low-cost models like the Envista, which was a key contributor to Buick's sales growth.

Macro· Apr 19

The US auto market may be impacted by tariffs, with low-cost models like Envista potentially being the hardest hit.
The Envista, a top-selling SUV for under $30,000, was previously a bright spot for General Motors' Buick brand.
The tariffs, imposed by President Trump, may reverse the sales gains made by Buick in the first quarter.

Generated by AI

Community

Of the messages about NVST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	21.62%	10.24%
Newcomers	—	—	78.38%	89.76%

Regulars· Feb 10

BofA raised its price target for NVST to $56 from $54, citing the company's strong Q4 results and guidance, with expectations for 6-8% organic growth and ongoing margin expansion.
Credit Suisse also raised its price target for NVST to $53 from $52, after the company's Q4 sales exceeded expectations, driven by strength in Specialty Products and Technologies.
Morgan Stanley maintained its Overweight rating for NVST and raised its price target to $52 from $48, following the company's Q4 results and its guidance for continued improvements in growth and margins in 2022.

Newcomers· Feb 10

Newcomers are focusing on Envista Holdings Corp's recent earnings report, highlighting the company's better-than-expected Q4 EPS and sales results.
The company's Q4 earnings call is a major topic, with several posts discussing the key metrics and updates from the call.
New investors are taking notice of the company's recent performance, with one post highlighting the stock's 7.9% move and another noting that the shares made a new 52-week high.

Generated by AI

News

BMO cuts Envista stock price target on China inventory headwind

1d agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

8d agoThe Globe and Mail

Envista Holdings (NVST), Why Is Investor Attention Building Now?

Envista Holdings (NVST) is set to present at the 2026 Global Healthcare Conference in New York on September 15, giving investors fresh commentary to weigh against recent share performance and fundamentals. Envista Holdings enters the conference with mixed momentum, with the share price up 8.02% year to date but a 30 day share price return down 13.86%, and longer term total shareholder returns of 12.16% over one year and a decline of 44.86% over five years. Compare Envista Holdings with a...

8d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Envista Holdings (NVST)

Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

11d agoThe Globe and Mail

Leerink Partners Keeps Their Buy Rating on Envista Holdings (NVST)

Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

11d agoThe Globe and Mail

Analysts Conflicted on These Healthcare Names: Envista Holdings (NVST), Alpha Teknova (TKNO) and Adaptive Biotechnologies (ADPT)

Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

11d agoThe Globe and Mail

Also Discussed

Investors talking about NVST also mention

#	Name	Attention
1	John Wiley & Sons Inc.WLY	0%new
2	Danaher Corp.DHR	0.02%+0.02
3	Dentsply Sirona Inc.XRAY	0%new
4	Align Technology Inc.ALGN	0%new
5	CGBS - Crown LNG Holdings Limited	——
6	Brookfield Business Corporation Class A Subordinate Voting SharesBBUC	0%-0.01
7	Fortive CorporationFTV	0%0
8	iRhythm Holdings, Inc.IRTC	0%0
9	Appfolio IncAPPF	0%0
10	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0

Envista Holdings Corp.

Healthcare
Medical Instruments & Supplies

Envista Holdings Corp. is a global dental products company that develops, manufactures, and markets a broad range of solutions for dental professionals. Its portfolio spans dental implants, orthodontic systems and aligners, imaging and digital workflow tools, restorative and endodontic products, and consumables used in everyday dental practice. The company serves clinical needs across prevention, diagnosis, treatment, and aesthetics, supporting dentists, oral surgeons, prosthodontists, and orthodontists with equipment, software, and branded consumables. Envista operates through two main business segments, Specialty Products & Technologies and Equipment & Consumables, and its products are used across dental offices, laboratories, and surgical settings worldwide. Headquartered in Brea, California, Envista holds a meaningful position in the dental technology and medical products market through a diversified family of dental brands.

Website

Location

Building E

Brea, CA, 92821-6208

United States

Social

What share of all stock conversation is about NVST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Feb 5

Envista Holdings ($NVST) reported Q4 2025 earnings, beating estimates with adjusted EPS of $0.38 and sales of $750.6M.
The company expects FY2026 adjusted EPS of $1.35-$1.45, representing a 7-13% increase in adjusted EBITDA.
Q4 2025 core sales growth accelerated to 10.8%, with a broad-based increase in both core sales and profitability.

Generated by AI

Sentiment

Of the messages about NVST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	97.56% +1.37
Bearish	—	—	0% -100	2.44% -1.37

Feb 10

Credit Suisse raises price target for NVST to $53, citing strength in Specialty Products/Technologies and positioning for continued improvements in growth and margins throughout 2022.
Morgan Stanley maintains an Overweight rating for NVST and raises the price target to $52, driven by the company's impressive innovation-driven beat and better-than-expected 2022 guidance.
BofA raises price target for NVST to $56, citing ongoing margin expansion and 6-8% organic growth targets, with the company's revamped portfolio and new products showing significant power.

Generated by AI

Topics

Of the messages about NVST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	52.23%
Analysts	—	—	50%	30.77%
Controversies	—	—	0%	0%
Earnings	—	—	0%	12.55%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	4.45%

Announcements· Apr 19

Envista, a top-selling SUV for under $30,000, could be hardest hit by President Trump's tariffs.
General Motors' Buick brand saw a 39% sales increase in the first quarter with a refreshed lineup, including the Envista.
Tariffs may impact low-cost models like the Envista, which was a key contributor to Buick's sales growth.

Macro· Apr 19

The US auto market may be impacted by tariffs, with low-cost models like Envista potentially being the hardest hit.
The Envista, a top-selling SUV for under $30,000, was previously a bright spot for General Motors' Buick brand.
The tariffs, imposed by President Trump, may reverse the sales gains made by Buick in the first quarter.

Generated by AI

Community

Of the messages about NVST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	21.62%	10.24%
Newcomers	—	—	78.38%	89.76%

Regulars· Feb 10

BofA raised its price target for NVST to $56 from $54, citing the company's strong Q4 results and guidance, with expectations for 6-8% organic growth and ongoing margin expansion.
Credit Suisse also raised its price target for NVST to $53 from $52, after the company's Q4 sales exceeded expectations, driven by strength in Specialty Products and Technologies.
Morgan Stanley maintained its Overweight rating for NVST and raised its price target to $52 from $48, following the company's Q4 results and its guidance for continued improvements in growth and margins in 2022.

Newcomers· Feb 10

Newcomers are focusing on Envista Holdings Corp's recent earnings report, highlighting the company's better-than-expected Q4 EPS and sales results.
The company's Q4 earnings call is a major topic, with several posts discussing the key metrics and updates from the call.
New investors are taking notice of the company's recent performance, with one post highlighting the stock's 7.9% move and another noting that the shares made a new 52-week high.

Generated by AI

Envista Holdings

Social

Feb 5

Feb 10

Announcements· Apr 19

Macro· Apr 19

Regulars· Feb 10

Newcomers· Feb 10

BMO cuts Envista stock price target on China inventory headwind

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

Envista Holdings (NVST), Why Is Investor Attention Building Now?

Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Envista Holdings (NVST)

Leerink Partners Keeps Their Buy Rating on Envista Holdings (NVST)

Analysts Conflicted on These Healthcare Names: Envista Holdings (NVST), Alpha Teknova (TKNO) and Adaptive Biotechnologies (ADPT)

Also Discussed

Envista Holdings Corp.

Company Information

Location

BMO cuts Envista stock price target on China inventory headwind

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

Envista Holdings (NVST), Why Is Investor Attention Building Now?

Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Envista Holdings (NVST)

Leerink Partners Keeps Their Buy Rating on Envista Holdings (NVST)

Analysts Conflicted on These Healthcare Names: Envista Holdings (NVST), Alpha Teknova (TKNO) and Adaptive Biotechnologies (ADPT)

Also Discussed

Social

Feb 5

Feb 10

Announcements· Apr 19

Macro· Apr 19

Regulars· Feb 10

Newcomers· Feb 10